
CEUS in Thyroid Assessment
Part of the EFSUMB CEUS Webinar Series, 'CEUS in Thyroid Assessment', takes place on Tuesday 28 October 2025 at 11.00 CEST and will be hosted by Sintesi on behalf of EFSUMB.
SPEAKER

Vito Cantisani
The Application of CEUS in the Diagnosis of Thyroid Diseases
Learning objectives:
1. To learn more on how to do CEUS for thyroid assessment
2. To know the major indications and limitations
SPEAKER

TInghui Yin
CEUS-guided thyroid Interventional
Learning objectives:
1. To evaluate the clinical utility of CEUS in fine-needle aspiration biopsy of thyroid nodules.
2. To investigate the predictive value of CEUS for early recurrence detection following thermal ablation in benign thyroid nodules.
3. To explore the integrative application of CEUS throughout the comprehensive management protocol of thyroid nodule ablation.
SPEAKER

Shiyan Li
The Role of CEUS in Interventional Ablation of Thyroid Tumors
Learning objectives:
1. Understand the advantages of CEUS over conventional B-mode ultrasound
- Explain how CEUS enhances real-time visualization of thyroid tumor vasculature and ablation zones, particularly in differentiating residual/recurrent lesions from post-ablation changes.
- Discuss the limitations of conventional ultrasound in identifying tumor margins and microvascular perfusion during ablation planning
2. Evaluate the role of CEUS in optimizing ablation guidance and efficacy
- Analyze how CEUS improves procedural accuracy by mapping tumor blood supply patterns and guiding precise needle placement during microwave or radiofrequency ablation.
- Describe its utility in intraprocedural monitoring to ensure complete ablation and avoid damage to critical adjacent structures (e.g., recurrent laryngeal nerve).
3. Assess post-ablation applications of CEUS in clinical follow-up
- Summarize CEUS’s ability to detect complications (e.g., hemorrhage, incomplete ablation) and evaluate treatment response in early follow-up stages
- Compare CEUS with other imaging modalities (e.g., CT, MRI) for cost-effectiveness and safety in patients with contraindications to iodinated contrast agents